Xenetic Biosciences, Inc. Reports First Quarter 2025 Financial Results and Provides Business Update
Continued progress of DNase I development program towards IND and first-in-human study for treatment of pancreatic carcinoma
Ended the quarter with $5.2 million of cash to fund operations
FRAMINGHAM, MA / / May 14, 2025 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers, today reported its financial results for the quarter ended March 31, 2025.
Recent Highlights
Announced that its collaboration partner, PeriNess Ltd., entered into a Clinical Study Agreement to advance development of DNase platform for the treatment of relapsed/refractory osteosarcoma and Ewing sarcoma; and
Continued pursuit of other strategic collaborations to advance the Company's technology.
"We remain focused on engaging with our strategic partners to participate in a series of exploratory studies to evaluate our systemic DNase I in combination with immunotherapy, chemotherapy, and radiotherapy in various oncology indications where there remains significant unmet need to advance our development programs forward. These partnerships allow us to advance our technology toward the clinic while utilizing our resources efficiently and minimizing our internal investment. Additionally, this development strategy opens up valuable opportunities to continue expanding our growing body of positive preclinical data that supports the use of DNase I across several cancer indications," commented James Parslow, Interim Chief Executive Officer and Chief Financial Officer of Xenetic.
Xenetic continues to advance its DNase-based technology towards Phase 1 clinical development for the treatment of pancreatic carcinoma and other locally advanced or metastatic solid tumors. Preliminary preclinical studies evaluating the combinations of DNase I with chemotherapy and DNase I with immuno-therapies in colorectal cancer models as well as CAR-T therapy have been completed.
Additionally, as previously announced in December 2024, Xenetic entered into a Clinical Trial Services Agreement with PeriNess, under which PeriNess will lead in the regulatory approval, operational execution and management of potential exploratory, investigator initiated studies of recombinant DNase as an adjunctive treatment in patients with pancreatic carcinoma and other locally advanced or metastatic solid tumors receiving chemotherapy and immunotherapy in Israeli medical centers.
Summary of Financial Results for First Quarter 2025
Net loss for the quarter ended March 31, 2025 was approximately $0.9 million. Revenue increased by approximately $0.1 million, or 16.1%, to approximately $0.6 million during the three months ended March 31, 2025 from approximately $0.5 million in the comparable quarter in 2024. Total operating costs and expenses for the three months ended March 31, 2025 decreased by approximately $244,000, or 13.7%, to approximately $1.5 million from approximately $1.8 million in the comparable quarter in 2024. The decrease was primarily due to a decrease in personnel costs and share-based expense related to the departures of the Company's former Chief Executive Officer and Chief Scientific Officer during the second quarter of 2024.
The Company ended the quarter with approximately $5.2 million of cash.
About Xenetic Biosciences
Xenetic Biosciences, Inc. is a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers. The Company's proprietary DNase technology is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in the progression of many human cancers. Xenetic is currently focused on advancing its systemic DNase program into the clinic as an adjunctive therapy for pancreatic carcinoma and other locally advanced or metastatic solid tumors.
For more information, please visit the Company's website at www.xeneticbio.com and connect on X, LinkedIn, and Facebook.
Forward-Looking Statements
This press release contains forward-looking statements that we intend to be subject to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release other than statements of historical facts may constitute forward-looking statements within the meaning of the federal securities laws. These statements can be identified by words such as "expects," "plans," "projects," "will," "may," "anticipates," "believes," "should," "intends," "estimates," "remain," "focus", "confidence in", "potential", "continues" and other words of similar meaning, including, but not limited to, all statements regarding expectations for our DNase-base oncology platform, including statements regarding: our focus on exploratory investigator-initiated clinical studies with institutional partners, our strategic collaborations, including expectations under our Clinical Trial Services Agreement with PeriNess regarding certain investigator initiated studies of recombinant DNase in Israeli medical centers, our overall development strategy, our continued pursuit of other strategic collaborations to advance the Company's technology, our focus on leveraging strategic partners to advance out technology toward the clinic, our commitment to the DNase program, our expectations regarding further expansion of our body of clinical data, our focus on advancing innovative immune-oncology technologies addressing difficult to treat cancers, the DNase technology improving outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in the progression of many human cancers, and our focus on advancing our systemic DNase program into the clinic as an adjunctive therapy for pancreatic carcinoma and locally advanced or metastatic solid tumors. Any forward-looking statements contained herein are based on current expectations and are subject to a number of risks and uncertainties. Many factors could cause our actual activities, performance, achievements, or results to differ materially from the activities and results anticipated in forward-looking statements. Important factors that could cause actual activities, performance, achievements, or results to differ materially from such plans, estimates or expectations include, among others, (1) unexpected costs, charges or expenses resulting from our manufacturing and collaboration agreements, including the Clinical Trial Services Agreement with PeriNess; (2) unexpected costs, charges or expenses resulting from the licensing of the DNase platform; (3) uncertainty of the expected financial performance of the Company following the licensing of the DNase platform; (4) failure to realize the anticipated potential of the DNase technologies; (5) the ability of the Company to obtain funding and implement its business strategy; and (6) other risk factors as detailed from time to time in the Company's reports filed with the SEC, including its annual report on Form 10-K, periodic quarterly reports on Form 10-Q, current reports on Form 8-K and other documents filed with the SEC. The foregoing list of important factors is not exclusive. In addition, forward-looking statements may also be adversely affected by general market factors, general economic and business conditions, including potential adverse effects of public health issues and geopolitical events, such as the conflicts in the Ukraine and in the Middle East, on economic activity, competitive product development, product availability, federal and state regulations and legislation, the regulatory process for new product candidates and indications, manufacturing issues that may arise, patent positions, litigation, and shareholder activism, among other factors. The forward-looking statements contained in this press release speak only as of the date the statements were made, and the Company does not undertake any obligation to update forward-looking statements, except as required by law.
Contact:
JTC Team, LLCJenene Thomas(908) 824-0775xbio@jtcir.com
SOURCE: Xenetic Biosciences, Inc.
View the original press release on ACCESS Newswire
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Boston Globe
24 minutes ago
- Boston Globe
Citizens Bank parent recruits former State Street exec to be its next CFO
The back-and-forth is, to some extent, a reflection of the fact that Boston-based State Street and Providence-based Citizens are by far New England's largest remaining publicly traded banks. State Street is the bigger of the two, though it focuses on services for institutional customers, while Citizens is a general-purpose commercial and consumer bank. Advertisement Citizens chief executive Bruce Van Saun said in a statement that Banerjee is a perfect fit for Citizens because of his leadership experience in financial services and his work overseeing 'transformation optimization programs' in the industry. His arrival comes as Citizens embarks on what Van Saun calls its 'Reimagining the Bank' initiative, aimed at using artificial intelligence to redesign key banking services. Advertisement The announcement comes a few weeks after Barclays posted a brief video interview with Banerjee on LinkedIn. 'My passion really came from a quote which says, 'It's not the fastest or the strongest or the most talented team which wins all the time but the team which always wins is the team that believes it can,' ' Banerjee said in that spot. 'So my passion is to ensure that ... we build that winning spirit in a team.' At the time, he was talking about Barclays. But pretty soon, he'll be putting his team-building skills to work at Citizens. This is an installment of our weekly Bold Types column about the movers and shakers on Boston's business scene. Jon Chesto can be reached at
Yahoo
32 minutes ago
- Yahoo
GE Appliances to invest $3B in US manufacturing
This story was originally published on Manufacturing Dive. To receive daily news and insights, subscribe to our free daily Manufacturing Dive newsletter. Dive Brief: GE Appliances plans to spend more than $3 billion in its U.S. operations and workforce over the next five years, the Louisville, Kentucky-based company said Wednesday. The investment will expand the appliance maker's air conditioning and water heating portfolio, increase production output and install new automation and capital equipment at its 11 manufacturing facilities and microfactories in the United States, according to the press release. Additionally, the funds will create more than 1,000 new jobs. The first phase of the five-year plan will begin at GE's facilities in Kentucky, Alabama, Georgia, Tennessee and South Carolina. Dive Insight: GE Appliances is a subsidiary of Haier Smart Home, a China-based company that specializes in appliances and consumer electronics. The company acquired GE Appliances from General Electric in 2016. GE Appliances' investment adds to the $3.5 billion it has spent in its U.S. operations since 2016, as the company has been working to move production back to the country from Mexico and China, according to its 2024 economic report. 'What we've done, what we're doing next isn't just good business, it's essential,' GE Appliances President and CEO Kevin Nolan said in his remarks during Wednesday's press conference at the company's global headquarters and manufacturing campus in Louisville. 'It's essential for our company, it's essential for our economy, and it's essential for American manufacturing, providing the goods that people need and the livelihood that they deserve.' The multi-billion-dollar pledge also builds on previously announced investments and expansions GE Appliances made over the summer. In June, the company completed a $180 million expansion of its subsidiary Roper Corp.'s cooking products manufacturing facility in LaFayette, Georgia. The expansion created more than 600 jobs and installed automated technology such as robotic cells to its production lines, assembling glass cooktops, program control boards and rotate units. The additions allow the LaFayette facility to expand production capacity to manufacture gas, electric and induction ranges to meet customer demand. The company also plans to ramp up the factory's production of its gas ranges, which were previously made in Mexico, according to the Aug. 13 press release. The company also announced in June a $490 million project at its Appliance Park manufacturing campus in Louisville, GE's largest site, which has five facilities. The money will go toward overhauling and redesigning the facility's front-load washer production lines as it aims 'to become the biggest American washer manufacturer,' according to the release. The funds will also enable the company to reshore production of its GE Profile brand washer and dryer combo and UltraFresh front-load washer line from China, according to Kentucky Gov. Andy Beshear's June 26 press release. Furthermore, the Louisville campus will serve as the central location for GE's research and development, product design and testing, according to Beshear's Aug. 13 press release. The recent announcements are part of the company's 'zero-distance' strategy that aims to bring appliances closer to its customers and consumers, Nolan said in a June 26 statement. 'This decision is our most recent product reshoring and aligns with the current economic and policy environment,' Nolan added. GE's phase one plan for three other sites aligns with its localized strategy, according to the Aug. 13 announcement. The multi-billion-dollar investment will add electric water heater and Geospring brand hybrid heat pump water heater manufacturing to its gas-powered water heater facility in Camden, South Carolina, according to the press release. Once the project is complete, it will double the plant's output and employment. The first phase for Camden is set to be implemented in early 2026. Elsewhere, GE plans to add two new models of its 2-ton Vertical Zoneline brand air conditioners to its air and water portfolio at its factory in Selmer, Tennessee. The facility is operated by GE subsidiary, Monogram Refrigeration. Additionally, GE's top-freezer refrigerator plant in Decatur, Alabama, will in-source 22-cubic-foot models to better support customer demand, according to the press release. Production is expected to ramp up by the end of the month. The appliance maker's other U.S. facilities are located in Elkhart, Indiana, and Stamford, Connecticut, according to its website. As GE Appliances installs new technology on its production lines, such as robotics, the changes call for an upskilled workforce. The company has taken steps to upskill and train current and potential employees over the past few years, according to its website. GE created a Louisville chapter of the Kentucky Federation for Advanced Manufacturing Education, a paid, hands-on work program for recent high school graduates. It also relaunched its apprenticeship program and created GEA2Day, a flexible workforce offering opportunities for high school and college students, as well as others seeking part-time positions, and gaining eligibility for tuition reimbursement up to $6,000 a year. The new multi-billion-dollar investment will enable the company to do more for its workforce, Nolan said in his remarks on Wednesday. 'The truth is, we need more people in manufacturing,' Nolan said. 'We need more programs that train, develop and invest in them.' 'This $3 billion commitment isn't just staying here in Kentucky, it's strengthening our entire American manufacturing footprint,' the CEO added. Recommended Reading GE Appliances completes $180M Georgia plant expansion
Yahoo
an hour ago
- Yahoo
Marlton Partners Files Preliminary Proxy Statement Related to Election of Directors for the 180 Degree Capital Board of Directors
CHICAGO, Aug. 15, 2025 /PRNewswire/ -- Marlton Partners L.P. (together with its affiliates and group members, "Marlton" or "we"), beneficial owners of approximately 5.8% of the outstanding stock of 180 Degree Capital Corp. (NASDAQ: TURN) ("TURN" or the "Company"), today announced that it has filed a preliminary proxy statement with the U.S. Securities Exchange and Commission to be used to solicit votes for the election of its four highly-qualified and independent director candidates – James C. Elbaor, Gabriel (Gabi) Gliksberg, Aaron Morris and Andrew (Andy) Greenberg (together, the "Nominees") - at the Company's upcoming Special Meeting of Shareholders scheduled for September 15. James C. Elbaor, Managing Member of Marlton, commented: "Yesterday, we filed our preliminary proxy related to our previously announced nomination of four highly-qualified director candidates to the TURN Board. As long-term shareholders, we remain committed to realizing TURN's full potential, and believe the September 15 meeting is a long overdue opportunity for Company shareholders to cast their vote on the composition of the Board. Since first engaging with the Company more than a year ago, we have remained steadfast in our intention of helping instill strong governance at TURN and to ensure that shareholder capital is respected. We look forward to TURN's owners having their rightful say on the future of the Company in September, and to speaking with shareholders directly about our nominees once we have a Definitive Proxy statement on file." About Marlton Partners Partners L.P. is a Chicago-based, privately held investment firm led by James C. Elbaor. The firm has a proven track record of success in investing in closed-end funds and acquires significant ownership positions in other assets where it believes long-term value can be enhanced through active ownership. Mr. Elbaor holds a B.A. from New York University and an M.B.A. from Columbia University. For more information about Marlton Partners L.P., please visit DISCLAIMERThis material does not constitute an offer to sell or a solicitation of an offer to buy any of the securities described herein in any state to any person. In addition, the discussions and opinions in this press release and the material contained herein are for general information only, and are not intended to provide investment advice. All statements contained in this press release that are not clearly historical in nature or that necessarily depend on future events are "forward-looking statements," which are not guarantees of future performance or results, and the words "may," "might," "could," "will," "should," "expect," "plan," "anticipate," "believe," "estimate," "predict," "potential" or "continue," the negative of these terms and other comparable terminology are generally intended to identify forward-looking statements. Any such forward-looking statements contained herein are based on current assumptions, estimates and expectations, but are subject to a number of known and unknown risks and significant business, economic and competitive uncertainties that may cause actual results to differ materially from expectations. Any forward-looking statements should be considered in light of those risk factors. The Participants (as defined below) caution readers not to rely on any such forward-looking statements, which speak only as of the date they are made. Certain information included in this press release is based on data obtained from sources considered to be reliable. No representation is made with respect to the accuracy or completeness of such data, and any analyses provided to assist the recipient of this press release in evaluating the matters described herein may be based on subjective assessments and assumptions and may use one among alternative methodologies that produce different results. Accordingly, any analyses should also not be viewed as factual and should not be relied upon as an accurate prediction of future results. Any figures are unaudited estimates and subject to revision without notice. The Participants disclaim any intent or obligation to publicly update or revise any such forward-looking statements to reflect any change in expectations or future events, conditions or circumstances on which any such forward-looking statements may be based, or that may affect the likelihood that actual results may differ from those set forth in such forward-looking statements. CERTAIN INFORMATION CONCERNING THE PARTICIPANTS Marlton Partners L.P., a Delaware limited partnership ("Marlton Partners"), together with the other Participants named herein, filed a preliminary proxy statement and an accompanying proxy card with the Securities and Exchange Commission ("SEC") on August 15, 2025 to be used to solicit votes for the election of its slate of highly-qualified director nominees at the special meeting of shareholders of 180 Degree Capital Corporation, a New York corporation (the "Company"), to be held on September 15, 2025, for the sole purpose of the election of directors. THE PARTICIPANTS STRONGLY ADVISES ALL SHAREHOLDERS OF THE COMPANY TO READ THE PROXY STATEMENT AND OTHER PROXY MATERIALS, INCLUDING A PROXY CARD, AS THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION. SUCH PROXY MATERIALS WILL BE AVAILABLE AT NO CHARGE ON THE SEC'S WEB SITE AT IN ADDITION, THE PARTICIPANTS IN THIS PROXY SOLICITATION WILL PROVIDE COPIES OF THE PROXY STATEMENT WITHOUT CHARGE, WHEN AVAILABLE, UPON REQUEST. REQUESTS FOR COPIES SHOULD BE DIRECTED TO THE PARTICIPANTS' PROXY SOLICITOR. The participants in the proxy solicitation are expected to be Marlton Partners, Marlton, LLC, James C. Elbaor, Aaron T. Morris, Gabriel D. Gliksberg, ATG Fund II, LLC, ATG Capital Management, LLC, and Andrew M. Greenberg (collectively, the "Participants"). As of the date hereof, Marlton Partners is the beneficial owner of 174,867 shares of common stock, par value $0.03, of the Company (the "Common Shares"). Marlton, LLC, a Delaware limited liability company ("Marlton") is the investment manager of Marlton Partners and, by virtue of that relationship, may be deemed to beneficially own the 174,867 Common Shares beneficially owned by Marlton Partners. Mr. Elbaor is the President of Marlton and, by virtue of that relationship, may be deemed to beneficially own the 174,867 Common Shares beneficially owned directly by Marlton. ATG Fund II LLC, a Delaware limited liability company ("ATG Fund II") is the beneficial owner of 300,004 Common Shares. ATG Capital Management, LLC, a Delaware limited liability company ("ATG Management"), is the managing member of ATG Fund II and, by virtue of that relationship, may be deemed to beneficially own the 300,004 Common Shares beneficially owned by ATG Fund II. Mr. Gliksberg is the managing member of ATG Management and, by virtue of that relationship, may be deemed to beneficially own the 300,004 Common Shares beneficially owned by ATG Management. As of the date hereof, Mr. Gliksberg is the beneficial owner of 87,862 Common Shares. As of the date hereof, Mr. Morris is the beneficial owner of 10,670 Common Shares. As of the date hereof, Mr. Greenberg is the beneficial owner of 10,000 Common Shares. As of the date hereof, the Participants may be deemed to collectively beneficially own 583,403 Common Shares. Media Contact:ASC AdvisorsTaylor Ingraham (203 992 1230)tingraham@ Investors Contact:James C. Elbaor (214-405-4141)James@ View original content: SOURCE Marlton Partners L.P. Sign in to access your portfolio
